Back to search

Peptide record

TPDB11512

Antibacterial Toxicity standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11512
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ToxinPred 3.0
standard
No
A 34-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KRFKKFFRKLKKSVKKRAKEFFKKPRVIGVSIPF
Physicochemical Analysis
C203H335N57O39
NDCQHMTWY
K
4198.25
12.45
15
1
13
+14
9.40
-0.753
62.94
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
1
A
4
R
0
N
0
D
0
C
1
E
0
Q
1
G
0
H
2
I
1
L
11
K
0
M
6
F
2
P
2
S
0
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 1 R: 4 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 1 H: 0 I: 2 L: 1 K: 11 M: 0 F: 6 P: 2 S: 2 T: 0 W: 0 Y: 0 V: 3
Chemical Descriptors
34
C203H335N57O39
4198.25
12.45
+14
9.40
-0.753
Evidence Records 9 records
Evidence 1 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against S. aureus ATCC 25923 (MIC 16 ug/ml), S.aureus ATCC 33591 (MIC 256 ug/ml) (MRSA-inactive) and 14 clinical strains (MIC 32-128
Evidence 2 Activity

Activity

MIC
Antibacterial
256 µg/mL

Target

S.aureus ATCC 33591

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus ATCC 25923 (MIC 16 ug/ml), S.aureus ATCC 33591 (MIC 256 ug/ml) (MRSA-inactive) and 14 clinical strains (MIC 32-128 ug/ml), E. coli ATCC 25922 or ATCC 51
Evidence 3 Activity

Activity

MIC
Antibacterial
8-16 µg/mL

Target

Escherichia coli ATCC 25922 or ATCC 51446

Source & Reference

dbAMP DRAMP

Other

us ATCC 33591 (MIC 256 ug/ml) (MRSA-inactive) and 14 clinical strains (MIC 32-128 ug/ml), E. coli ATCC 25922 or ATCC 51446 (MIC 8-16 ug/ml), K. pneumoniae ATCC 13883 or ATCC 700603 (MIC 4-32 ug/ml).
Evidence 4 Activity

Activity

MIC
Antibacterial
4-32 µg/mL

Target

Klebsiella pneumoniae ATCC 13883 or ATCC 700603

Source & Reference

dbAMP DRAMP

Other

4 clinical strains (MIC 32-128 ug/ml), E. coli ATCC 25922 or ATCC 51446 (MIC 8-16 ug/ml), K. pneumoniae ATCC 13883 or ATCC 700603 (MIC 4-32 ug/ml).
Evidence 5 Activity

Activity

22% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
22% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 6 Activity

Activity

15% Hemolysis
Toxicity
125 µg/mL
Hemolytic Cytotoxic
15% Hemolysis | 125 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 7 Activity

Activity

8% Hemolysis
Toxicity
31.2 µg/mL
Hemolytic Cytotoxic
8% Hemolysis | 31.2 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 8 Activity

Activity

25% Cell death
Toxicity
106.5 µg/mL
Cytotoxic
25% Cell death | 106.5 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 9 Activity

Activity

% Hemolysis
Toxicity
5 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.29392557] 5% haemolysis at 1.0 µg/ml, 5% haemolysis at 2.0 µg/ml, 5% haemolysis at 4.0 µg/ml, 5% haemolysis at 8.0 µg/ml, 7% haemolysis at 16.0 µg/ml, 9% haemolysis at 31.2 µg/ml, 13% haemolysis at 62.5 µg/ml, 17% haemolysis at 125.0 µg/ml, 19% haemolysis at 250.0 µg/ml, 23% haemolysis at 500.0 µg/ml, 24% haemolysis at 1000.0 µg/ml against human red blood cells | Cytotoxicity: [Ref.29392557] The cell viability of HUVEC at the peptide concentration of 35.5 µg/ml, 71 µg/ml and 113 µg/ml is 127%, 100% and 76%. ##The cell viability of H9c2 at the peptide concentration of 35.5, 71, and 113 µg/ml is 132, 100, and 80%.

Target

erythrocytes

Source & Reference

NA
DRAMP
J Microbiol. 2018 Feb 56(2):128-137.